Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

ACC 2024 Congress

Catch up on all the top stories and latest evidence in cardiology research with our ACC 2024 Congress hub page.
ADVANCED SEARCH
Log in
Top
Clinical & Experimental Metastasis
Metadata
Title
Expression and activation of pro-gelatinase A by human melanoma cell lines with different tumorigenic potential
Authors
François Capon
Hervé Emonard
William Hornebeck
François-Xavier Maquart
Philippe Bernard
Publication date
01-10-1999
Publisher
Kluwer Academic Publishers
Published in
Clinical & Experimental Metastasis / Issue 6/1999
Print ISSN: 0262-0898
Electronic ISSN: 1573-7276
DOI
https://doi.org/10.1023/A:1006674709232

Other articles of this Issue 6/1999

Clinical & Experimental Metastasis 6/1999 Go to the issue

OriginalPaper

Phosphodiesterase type III inhibitor, cilostazol, inhibits colon cancer cell motility

OriginalPaper

Oral administration of muscle derived small molecules inhibits tumor spread while promoting normal cell growth in mice

OriginalPaper

Cytogenetic analyses of secondary liver tumors reveal significant differences in genomic imbalances between primary and metastatic colon carcinomas

OriginalPaper

Co-inoculation of human and murine carcinoma cells induces reciprocal suppression of metastasis by both cell lines

OriginalPaper

Hepatocyte growth factor promotes migration of human hepatocellular carcinoma via phosphatidylinositol 3-kinase

OriginalPaper

A nude mouse model of human osteosarcoma lung metastases for evaluating new therapeutic strategies
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits